Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations

被引:80
作者
Marras, C
Lang, A
Krahn, M
Tomlinson, G
Naglie, G
机构
[1] Univ Toronto, Hlth Network, Toronto Western Hosp, Div Neurol, Toronto, ON, Canada
[2] Univ Toronto, Hlth Network,Div Clin Decis Making & Hlth Care Re, Toronto Gen Hosp, Toronto Gen Res Inst, Toronto, ON, Canada
[3] Univ Toronto, Hlth Network, Dept Radiol, Toronto, ON, Canada
[4] Univ Toronto, Dept Biostat, Toronto, ON, Canada
[5] Univ Toronto, Hlth Network, Div Gen Internal Med, Toronto, ON, Canada
[6] Toronto Rehabil Inst, Geriatr Program, Toronto, ON, Canada
[7] Univ Toronto, Dept Med, Toronto, ON, Canada
[8] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada
关键词
dyskinesia; motor fluctuations; quality of life; Parkinson's disease; dopamine agonists; levodopa;
D O I
10.1002/mds.10642
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The impact of dyskinesias and motor fluctuations on quality of life (QOL) at various stages in the course of Parkinson's disease (PD) is not well understood. In 301 subjects with early PD enrolled in a clinical trial (CALM-PD), we quantified the impact of motor complications on QOL and investigated how this changes over time. We also compared QOL related to demographic and treatment characteristics. The presence of dyskinesias was associated with visual analogue scale (VAS) scores 3.0 of 100 points higher (better) than those without dyskinesias in years I to 2, even when adjusting for Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. The positive association between dyskinesias and QOL scores was more marked in older patients. In years 3 to 4, dyskinesias no longer had a significant relationship with QOL. Younger subjects had higher VAS scores. Gender, motor fluctuations, and treatment regimen had no significant association with QOL, although a trend was found toward a small negative effect of motor fluctuations on QOL. We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients. (C) 2003 Movement Disorder Society.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 15 条
[1]   Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life [J].
Damiano, AM ;
McGrath, MM ;
Willian, MK ;
Snyder, CF ;
LeWitt, PA ;
Reyes, PF ;
Richter, RR ;
Means, ED .
QUALITY OF LIFE RESEARCH, 2000, 9 (01) :87-100
[2]  
*EUR GROUP, 1990, HLTH POLICY, V12, P199
[3]  
Fahn S, 1987, Recent Dev. Park. Dis, P153
[4]   Risk factors for levodopa-induced dyskinesias in Parkinson's disease [J].
Grandas, F ;
Galiano, ML ;
Tabernero, C .
JOURNAL OF NEUROLOGY, 1999, 246 (12) :1127-1133
[5]   Health related quality of life in Parkinson's disease:: a prospective longitudinal study [J].
Karlsen, KH ;
Tandberg, E ;
Årsland, D ;
Larsen, JP .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (05) :584-589
[6]   EARLY DEVELOPMENT OF LEVODOPA-INDUCED DYSKINESIAS AND RESPONSE FLUCTUATIONS IN YOUNG-ONSET PARKINSONS-DISEASE [J].
KOSTIC, V ;
PRZEDBORSKI, S ;
FLASTER, E ;
STERNIC, N .
NEUROLOGY, 1991, 41 (02) :202-205
[7]   Ten-year follow-up of three different initial treatments in de-novo PD - A randomized trial [J].
Lees, AJ ;
Katzenschlager, R ;
Head, J ;
Ben-Shlomo, Y .
NEUROLOGY, 2001, 57 (09) :1687-1694
[8]  
*PARK STUD GROUP, IN PRESS ARCH NEUROL
[9]  
Parkinson Study Group, 2000, JAMA, V284, P1931
[10]  
Pechevis M, 2001, PARKINSONISM RELAT D, V7, P106